返回 
加入收藏
参麦注射液联合吉西他滨和顺铂治疗肺腺癌的疗效及对CT净增值的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 参麦注射液联合吉西他滨和顺铂治疗肺腺癌的疗效及对CT净增值的影响 |
| TITLE： | |
| 摘要： | 目的：观察参麦注射液联合吉西他滨和顺铂治疗肺腺癌的疗效、安全性及对CT净增值的影响。方法：86例肺腺癌患者随机均分为对照组和观察组。对照组患者给予注射用盐酸吉西他滨1 000～1 250 mg/m2，加入0.9％氯化钠注射液250 ml中，d1、8，静脉滴注，每日1次+顺铂注射液25 mg/m2，加入0.9％氯化钠注射液250 ml中，d1-3，静脉滴注，每日1次；观察组患者在对照组治疗的基础上给予参麦注射液50 ml，加入5％葡萄糖注射液250 ml中，静脉滴注，每日1次，连用21 d。两组均以21 d为1个周期，连续治疗3个周期后评价疗效。观察两组患者治疗前后T淋巴细胞群（CD3+、CD4+、CD8+、CD4+/CD8+）、Piper疲乏自我评估量表（PFS）评分、癌症生存质量评估问卷（QLQ-30）评分 、CT净增值及毒副反应。结果：观察组患者总有效率显著高于对照组，白细胞计数下降、血小板计数下降、胃肠道反应发生率均显著低于对照组，差异均有统计学意义（P＜0.05）。观察组患者T淋巴细胞群治疗前后比较，差异均无统计学意义（P＞0.05）；对照组患者治疗后T淋巴细胞群均显著低于同组治疗前和观察组，差异均有统计学意义（P＜0.05）。两组患者PFS评分、CT净增值均显著低于同组治疗前，且观察组低于对照组；QLQ-30评分显著高于同组治疗前，且观察组高于对照组，差异均有统计学意义（P＜0.05）。结论：参麦注射液联合吉西他滨和顺铂治疗肺腺癌疗效显著，可改善免疫功能，减轻疲乏感，降低CT净增值，且安全性较好。 |
| ABSTRACT： | OBJECTIVE：To observe the efficacy and safety of Shenmai injection combined with gemcitabine and cisplatin in the treatment of lung adenocarcinoma and its effects on changes of CT net added value. METHODS：86 patients with III B and IV lung adenocarcinoma were randomly divided into control group and observation group. Control group was treated with 1 000-1 250 mg/m2 Gemcitabine hydrochloride for injection，adding into 250 ml 0.9％ Sodium chloride injection by intravenous infusion， d1，8， once a day+25 mg/m2 Cisplatin injection，adding in to 250 ml 0.9％ Sodium chloride injection by intravenous infusion， once a day， d1-3. Observation group was additionally treated with 50 ml Shenmai injection， adding into 250 ml 5％ Glucose injection by intravenous infusion， once a day， for continuous 21 d. 21 d was regarded as 1 course， and the efficacy was evaluated after 3 courses. T lymphocyte populations （CD3+，CD4+，CD8+，CD4+/CD8+）， Piper fatigue self-assessment scale （PFS） score， cancer quality of life assessment questionnaires （QLQ-30） score， CT net added value and toxicity before and after treatment reactions in 2 groups were observed. RESULTS：The total effective rate in observation group was significantly higher than control group， the incidences of leukopenia， thrombocytopenia and gastrointestinal reactions were significantly lower than control group， the differences were statistically significant（P＜0.05）. There was no significant difference in the T lymphocyte populations in observation group before and after treatment（P＞0.05）， T lymphocyte populations in control group were significantly lower than before and observation group， the differences were statistically significant（P＜0.05）； PFS score and CT net added value in 2 groups were significantly lower than before， and observation group was lower than control group， QLQ-30 score was significantly higher than before， and observation group was higher than control group， the differences were statistically significant（P＜0.05）. And there was no significant difference in the incidence of adverse reactions（P＞0.05）. CONCLUSIONS： The efficacy of Shenmai injection combined with gemcitabine and cisplatin regimen in the treatment of lung adenocarcinoma is obvious， it can improve the immunity， reduce the sense of fatigue and decrease CT net added value， with good safety. |
| 期刊： | 2016年第27卷第9期 |
| 作者： | 汤晓牧，刘洁，赵衡 |
| AUTHORS： | TANG Xiaomu，LIU Jie，ZHAO Heng |
| 关键字： | 肺腺癌；吉西他滨；顺铂；参麦注射液；疗效；安全性 |
| KEYWORDS： | Lung adenocarcinoma； Gemcitabine； Cisplatin； Shenmai injection； Efficacy； Safety |
| 阅读数： | 302 次 |
| 本月下载数： | 1 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
